Results 101 to 110 of about 24,922 (273)

Modeling cerebral palsy in animals

Developmental Medicine &Child Neurology, Volume 68, Issue 2, Page 158-174, February 2026.
Abstract Advancements in the treatment of cerebral palsy depend on animal research. Yet, most animal models have not been fully evaluated for spasticity and dystonia using clinically relevant measures of altered tone or movement patterns, which form the basis for diagnosing people with the condition.
Katharina A. Quinlan, Emily J. Reedich, Elvia Mena Avila, Brendan C. Moline, Landon T. Genry, Megan R. Detloff, Benjamin R. Katholi, Deborah Gaebler‐Spira, Bhooma R. Aravamuthan   +8 more
wiley   +1 more source

Biosecurity Threat Posed by Botulinum Toxin

Toxins, 2019
The deliberate release of biological agents with terrorist or criminal intent continues to pose concerns in the current geopolitical situation. Therefore, attention is still needed to ensure preparedness against the potential use of pathogens as ...
Orlando Cenciarelli, Paul William Riley, Agoritsa Baka   +2 more
doaj   +1 more source

Botulinum Neurotoxin Injections in Children with Self-Injurious Behaviors [PDF]

, 2023
Mariam Hull, Mered Parnes, Joseph Jankovic   +2 more
openalex   +1 more source

Capsaicin protects neuromuscular junctions from the inhibitory effects of botulinum neurotoxin A [PDF]

, 2008
Within 24 hrs after injecting botulinum neurotoxin A (BoNT/A) into the hindlimb, mice lost the toe spread reflex and developed progressive muscle weakness. At the same time, the compound muscle action potential amplitude decreased. Injection of capsaicin
Baskaran Thyagarajan, Carmen Garcia, Joseph McArdle, Joseph Potian, Kormakur Hognason, Natalia Krivitskaya   +5 more
core   +1 more source

Fragment C of Tetanus Toxin : New Insights into Its Neuronal Signaling Pathway [PDF]

, 2012
When Clostridium tetani was discovered and identified as a Gram-positive anaerobic bacterium of the genus Clostridium, the possibility of turning its toxin into a valuable biological carrier to ameliorate neurodegenerative processes was inconceivable ...
Acheson, Aguilera, Ana C. Calvo, Anderson, Barati, Boquet, Borasio, Bordet, Brooks, Calappi, Carlton, Chaib-Oukadour, Chaib-Oukadour, Check, Chen, Chen, Ciriza, Coen, Conway, Cosman, Cowie, Deinhardt, Deinhardt, Deinhardt, Emsley, Evinger, Firor, Fishman, Flexner, Fotinou, Gil, Gil, Gil, Gil, Habermann, Habermann, Harvey, Helting, Herreros, Herreros, Humeau, Inserte, Ipsen, Jayaraman, Jayaraman, Johnson, Johnson, Johnson, José Aguilera, Lalli, Landsteiner, Larsen, Lazarovici, Louch, Manning, Manwaring, Martini, Mendieta, Menestrina, Miana-Mena, Miana-Mena, Miana-Mena, Mochida, Montal, Moreno-Igoa, Moreno-Igoa, Neubauer, Noguchi, Oliveira, Pelliccioni, Pellizari, Pilar Zaragoza, Raquel Manzano, Roaf, Rosario Osta, Roux, Rummel, Sara Oliván, Sherrington, Siade, Simpson, Sinha, Skaper, Skeldal, Sugiyama, Sutton, Thorne, Twiss, Ungar, Van Heyningen, Van Heyningen, Van Heyningen, Van Heyningen, Wang, Wassermann, Wright   +95 more
core   +3 more sources

Botulinum neurotoxins

, 2023
Botulinum neurotoxins (BoNTs) are the most potent toxins known to man, with less than 1 μg of pure toxin being enough to kill an adult man. Despite the high toxicity, BoNTs are widely used in cosmetics and in medicine for the treatment of an increasing number of medical conditions.
openaire   +1 more source

Synaptotagmin Binding to Botulinum Neurotoxins

Biochemistry, 2019
Botulinum neurotoxins (BoNTs) are exceptionally toxic proteins that cause paralysis but are also extensively used as treatment for various medical conditions. Most BoNTs bind two receptors on neuronal cells, namely, a ganglioside and a protein receptor.
Markel Martínez-Carranza, Pilar Blasco, Robert Gustafsson, Min Dong, Ronnie Per-Arne Berntsson, Göran Widmalm, Pål Stenmark   +6 more
openaire   +4 more sources

Building on European Reference Network for Rare Neurological Diseases (ERN‐RND) Experience: Integrating Motor and Non‐Motor Assessment in Pediatric Movement Disorders

Movement Disorders, EarlyView.
Maria Eugenia Amato, Juan Darío Ortigoza‐Escobar   +1 more
wiley   +1 more source

Review of published research on primary dysautonomia of domestic animals

Veterinary Record, Volume 198, Issue 1, Page e30-e40, 3/10 January 2026.
Abstract An article published in 1992 by Marion M. Pollin and I.R. Griffiths reviewed the topic of primary dysautonomias of the autonomic nervous system of unidentified origin in multiple domestic species, specifically cats, dogs and horses. Thirty‐one years later, we appear no closer to identifying the causal agents of these strikingly similar ...
Tanith Harte, David Smith, Jo Moore, Beth Wells   +3 more
wiley   +1 more source

Emerging Opportunities for Serotypes of Botulinum Neurotoxins

Toxins, 2012
Background: Two decades ago, botulinum neurotoxin (BoNT) type A was introduced to the commercial market. Subsequently, the toxin was approved by the FDA to address several neurological syndromes, involving muscle, nerve, and gland hyperactivity.
John Tapia-Núñez, Michael S. Okun, Aparna Wagle Shukla, Ramon L. Rodriguez, J. Glenn Morris, Zhongxing Peng Chen   +5 more
doaj   +1 more source